VKTX VIKING THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, VIKING THERAPEUTICS INC reported revenue of $0, net income of −$128M and diluted EPS of −$1.10; over the last four quarters revenue was $0 and net income −$535M; for the fiscal year ended December 2025 revenue was $0.

VKTX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$393M, net income −$360M (margin n/a), EPS −$3.19
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$151M, net income −$110M (margin n/a), EPS −$1.01
• Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$101M, net income −$85.9M (margin n/a), EPS −$0.91
• Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$70.4M, net income −$68.9M (margin n/a), EPS −$0.90
• Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$55.7M, net income −$55.0M (margin n/a), EPS −$0.71

VKTX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $0, net income −$128M, EPS −$1.10
• Quarter ended Mar 31, 2026: revenue $0, net income −$158M, EPS −$1.37
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income −$158M, EPS −$1.39
• Quarter ended Sep 30, 2025: revenue $0, net income −$90.8M, EPS −$0.81
• Quarter ended Jun 30, 2025: revenue $0, net income −$65.6M, EPS −$0.58
• Quarter ended Mar 31, 2025: revenue $0, net income −$45.6M, EPS −$0.41
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$35.4M, EPS −$0.33
• Quarter ended Sep 30, 2024: revenue $0, net income −$24.9M, EPS −$0.22
• Quarter ended Jun 30, 2024: revenue $0, net income −$22.3M, EPS −$0.20
• Quarter ended Mar 31, 2024: revenue $0, net income −$27.4M, EPS −$0.26
• Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$24.6M, EPS −$0.24
• Quarter ended Sep 30, 2023: revenue $0, net income −$22.5M, EPS −$0.23
• Quarter ended Jun 30, 2023: revenue $0, net income −$19.2M, EPS −$0.19
• Quarter ended Mar 31, 2023: revenue $0, net income −$19.5M, EPS −$0.25
• Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$19.6M, EPS −$0.25
• Quarter ended Sep 30, 2022: revenue $0, net income −$15.8M, EPS −$0.21
• Quarter ended Jun 30, 2022: revenue $0, net income −$17.4M, EPS −$0.23
• Quarter ended Mar 31, 2022: revenue $0, net income −$16.1M, EPS −$0.21
• Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$12.4M, EPS −$0.15
• Quarter ended Sep 30, 2021: revenue $0, net income −$13.2M, EPS −$0.17

VKTX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$279M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$87.8M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$73.4M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$48.4M, share buybacks $6.80M
• Fiscal year ended Dec 2021: operating cash flow −$47.6M, share buybacks n/a

VKTX balance sheet

• Jun 30, 2026: cash $126M, total assets $522M, total liabilities $114M, shareholders' equity $408M
• Mar 31, 2026: cash $118M, total assets $608M, total liabilities $106M, shareholders' equity $502M
• Dec 31, 2025: cash $166M, total assets $716M, total liabilities $76.7M, shareholders' equity $639M
• Sep 30, 2025: cash $100M, total assets $739M, total liabilities $26.4M, shareholders' equity $713M
• Jun 30, 2025: cash $33.9M, total assets $828M, total liabilities $32.4M, shareholders' equity $795M
• Mar 31, 2025: cash $37.9M, total assets $867M, total liabilities $20.1M, shareholders' equity $847M
• Dec 31, 2024: cash $26.7M, total assets $908M, total liabilities $28.0M, shareholders' equity $880M
• Sep 30, 2024: cash $50.3M, total assets $938M, total liabilities $26.4M, shareholders' equity $911M

What is VKTX's revenue?

VIKING THERAPEUTICS INC reported $0 of revenue over its last four quarters, through June 30, 2026.

Is VKTX profitable?

No. VIKING THERAPEUTICS INC lost $535M over the last four quarters.

What is VKTX's EPS?

Diluted earnings per share over the last four quarters were −$4.67; −$1.10 in the latest quarter.

VKTX ownership and insider trades · All stocks